Fig. 2
In-vitro cytotoxicity and cytokines production and in-vivo anti-tumor activity of CAR-IL15/IL-15Rα-T cells. Viable cells of CAR-T cells cultured without IL-2 (A) and with IL-2 (B). Cytokine production of CAR-T cells co-cultured with gastric cancer cell lines HGC27 (C) and MKN45 (D) under effector-to-target ratio of 5:1, 2:1 and 1:1 for 24 h by ELISA assay. E In-vitro cytotoxicity of CAR-T cells against HGC27 and MKN45 under effector-to-target ratio of 5:1 for 24 h and 48 h by bioluminescence assay. F In-vitro cytotoxicity of CAR-T cells against HGC27 and MKN45 under effector-to-target ratio of 2:1 for 24 h, 48 h and 72 h by bioluminescence assay. G Experiment setup for (H), (I) and (J). Tumor volume (H), bioluminescence imaging (I) and Mice body weight (J) of HGC27 mouse xenografts after treatment with 5 × 106 15B6 or 15B6ss CAR-T cells. Asterisks in figures represent significant difference (*p < 0.05, **p < 0.01) between two groups, calculated using Independent-samples T test by IBM SPSS statistics 20